- Oral NSAIDs are commonly used for relieving pain, reducing inflammation, and managing fever in conditions such as arthritis, musculoskeletal injuries, and menstrual cramps
- The market is primarily driven by the increasing prevalence of chronic pain disorders, growing geriatric population, and rising demand for non-opioid pain management alternatives
- North America is expected to dominate the oral nonsteroidal anti-inflammatory drugs market due to advanced healthcare infrastructure, high awareness about pain management, and strong presence of pharmaceutical companies
- Asia-Pacific is expected to be the fastest growing region in the oral nonsteroidal anti-inflammatory drugs market during the forecast period due to increasing healthcare access, expanding middle-class population, and rising incidence of chronic conditions
- The arthritis segment is expected to dominate the market with a market share of 38.5%, attributed to high global prevalence of osteoarthritis and rheumatoid arthritis, particularly among the aging population
Frequently Asked Questions
The market is segmented based on Global Oral Nonsteroidal Anti-Inflammatory Drugs Market Segmentation, By Disease Indication, Arthritis, Migraine, and Ophthalmic Diseases), Drugs (Over-the-counter Drugs and Prescription), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2032
.
The Global Oral Nonsteroidal Anti Inflammatory Drugs Market size was valued at USD 23.19 USD Billion in 2024.
The Global Oral Nonsteroidal Anti Inflammatory Drugs Market is projected to grow at a CAGR of 5.86% during the forecast period of 2025 to 2032.
The major players operating in the market include Bayer AG , Pfizer Inc , Reckitt Benckiser Group PLC , Novartis AG ,DAIICHI SANKYO COMPANY, LIMITED , Zydus Group , Lupin , GSK Plc , Glenmark Pharmaceuticals Inc , Amneal Pharmaceuticals , AstraZeneca .
The market report covers data from the North America.
